Scancell Share Discussion Threads

[inanaco] 13/4/2023 13:29

You Don't present a "DUD" .....

Chill ....

it would be interesting, if the Market catches up with Trinity, as they are going up faster with revaluations

[j777j] 13/4/2023 12:58

Looks like a revisit to 25p next stop

[octopus100] 13/4/2023 11:52

When was the Youtube link released.
What is there an embargo on and why?

[chilltime] 13/4/2023 11:09

18th April

It states embargoed re the presentation, but so do many others.

However, there will be by that time 2 months worth of missing data from the trials, so in theory they can't present that unless it's shared prior to the market.

Given that certain experts from the relevant trial hospitals seem to be there then surely there is something good to talk about, including points we are unaware of.

Further they list Modi with CPIs, given the last update only identifies 1 patient so far, the surely they have more data and more patients by now.

Perhaps that as yet unidentified patient on the macmillan forum who has seen major regression is a Modi or Modi plus CPI patient.

Hopefully an RNS soon, an update on progress. Then one wonders on the timing of the Vulpes note and related buying in the last week or so pre note/presentation event.

The first real public airing of the results so far, in the Bio investment hungry US.

[marcusl2] 13/4/2023 10:07

iScib-1 with Avidimab and additional epitopes will now cover almost all patients. Scib-1 was 40%.


A barrier to licensing Scib was that and electroporation which has been replaced with Pharmajet.

I wonder when they will do a deal? Maybe wait for cracking iScib data?

[chilltime] 13/4/2023 09:50

The Scib1 results explained in that video are stunning

For those interested the graph explaining it is at 10 mins 25 secs.

16 patients, skin cancer.

It shows the 5 years prior, with operations for each patient to remove lesions.

The first 10 in the list had a combined 25 operations/;lesions removed in the run up to starting Scib and most had lesions in the months before starting Scib.

After starting Scib those 10 were disease free for 5 years (the test period) but were all actually still disease free from 5 to 7 years. The record was live at the time, so what happened after is obviously not recorded.

But 62.5% disease free immediately after taking Scib is very impressive.

They added a CPI for those not responding with further impact on the disease for them

As I recall from posts here only 40% of the sufferers are suitable for Scib1 but iScib1+ 100% of sufferers.

So with 62.5% all clear as a starting point then it make me wonder what they have when Lindy said "If you liked Scib, you'll love iScib"

[inanaco] 13/4/2023 08:47

Checkpoint inhibitors (CPI) have marginal effect on CD4 Killer T cells hence scancell never tested the synergy in the mouse model

[chilltime] 13/4/2023 08:43

I saw that Nigel and timed with just having listened to the ex CEO Dr Holloway.

Interesting then re Modi.

In the case of citrullination and homocitrullination.

It's the conversion of aminoacids, BUT at the end point it's reached its limit, it can't chemically change into something else.

So Scancell worked on that to target it, producing a synthesised match to cause the antigen effect to produce CD4 T cells to attack it.

As explained CPIs well too. Cancers put the brakes on T cell immune responses, CPIs like Keytruda take off that brake (but only for about 30% of the population), then the accelerator is pressed, but if you have no gas (cell response) then nothing will happen, a vaccine like Scib/Moditope adds the fuel in the form of the T cell response, so the fuel to combat the cancer is now in place and can attack and kill cancer cells.

[inanaco] 13/4/2023 07:42

Nigel

1.5 min in



pretty well covers the BBC ....

along with my recent posts on this very subject of Enolase and Vimentin

[nigelpm] 12/4/2023 19:53

Interesting -

[chilltime] 12/4/2023 17:47

And from that I can see the modi vaccine timelines.

Week 3,6,9,12, then every 12 weeks for up to 2 years, if needed

[chilltime] 12/4/2023 17:43

I haven't seen this before. A presentation by the ex CEO.

It certainly helped me understand with raised eyebrows about Scib results which I had pretty much ignored. A simple analogy of brakes, accelerator, add fuel to describe what Scancell tech overcomes.

From about 9 mins covers Scib and some outstanding results.

It then moves onto Modi explaining the 100% survival of mice in unprecedented results.

Well worth watching, it explains what they are doing with BionTech too.

[dominiccummings] 12/4/2023 17:40

Always worth checking Vulpes website!


h t tps://vulpesinvest.com/wp-content/uploads/2023/04/Scancell-report-20230412.pdf

Here's the link (take spaces out of 'htt')

[chilltime] 12/4/2023 17:20

Vulpes

They use professor Peter James to do their DD on this type of company. They have had a 100% success rate with him.

He was asked to find the right investment and researched something like 20 of these type of companies over 6 months or more.

I believe he said Scancell is the most exciting company in the field that he has seen in 10 years. He reviewed the Mouse data on modi which is described as unprecedented.

On the back of his review Vulpes invested, and they are indeed very excited about the progress and potential and have been for some time.

The details I believe are in this interview, which I can't access at the moment

[chillpill] 12/4/2023 16:49

I have little doubt if this was a US company quoted on Nasdaq it would have a market cap well in excess of $1bn.

[connello] 12/4/2023 16:48

Why would anyone Be selling?

[chilltime] 12/4/2023 15:20

25th Jan

Fourteen patients enrolled and dosed in the expansion phase of the monotherapy arms in the multicentre Phase 1/2 Modi-1 clinical trial (ModiFY). First patient dosed in Cohort 3 of ModiFY in combination with a checkpoint inhibitor (CPI). There have been no safety issues to date.

21st Feb

To date, 23 patients have been vaccinated with Modi-1 and all have had skin reactions at the injection sites consistent with a delayed-type hypersensitivity (DTH) reaction indicative of a T cell response. So far, initial clinical responses have been assessed in 14 patients reaching the first imaging evaluation timepoint at week 8.

So for now I'd guess 40 or so maybe, now dosed. I see 9 hospitals are recruiting for it.

[plasybryn] 12/4/2023 15:14

What a great post by Chester on LSE. I do hope he/she doesn't mind me copying it over here.Vulpes Assessment is Very ImportantAfter a full and exhaustive Due Diligence, Vulpes was the first large investment vehicle to commit many millions of pounds.Would Redmile have come along with their £40M without them ? Its really difficult to know for sure, so I always see Vulpes as the initial Green Light investor.Why would Vulpes release such a document today, two days prior to the lifting of the AACR embargo of the Presentation details ? I see this as a well timed and coordinated build up to our next ModiFY RNS. The tone taken by this report is extremely positive and I do hope it's because they know 'a little to a lot' more than our good selves. The Embargo lifts on Friday, I've no idea what time of day, with the Lindy Durrant presentation nest Tuesday, so its been released in very short notice to the main event.Speculation is rife and right now we have very good cause.Good luck to all shareholders Recent or Long Term, a very successful Scancell is all that we wish for, that's not much to ask for is it....... : )Chester.

[chilltime] 12/4/2023 15:10

Octopus
re

I've lost track of where the 138 patients are at in their recruitment and who and when has been vaccinated.


The initial recruitment was for 108 across 4 cancer types, so about 27 patients per cancer.

The 138 includes the combo (Keytruda) so I take it 30 on the combo trial.

That patient posts mentioned, it could be anything of course but could be Modi or Modi plus Keytruda.

Previous posts on the forum suggested more than one has seen success, that may well be one of them on a new patient.

Rumours have been around re others seeing shrinkage beyond 30%.

We'll see as and when Scancell release details.

[dominiccummings] 12/4/2023 13:51

h t tps://vulpesinvest.com/wp-content/uploads/2023/04/Scancell-report-20230412.pdf

Here's the link (take spaces out of 'htt')

[markingtime] 12/4/2023 12:35

Yes - I agree with all of that. The new Chair will, I hope, arrange for that imbalance to be corrected, so that the commercial potential is not left to one side in pursuit of the science. Vulpes' Diggle will undoubtedly be pressing him at the Board. Of course, the fact that it is a pretty pure "science play" is actually a plus for any buyer.......especially as it may be "too cheap".

[chilltime] 12/4/2023 12:30

The share price is derisory due to the very point they raise, Scancell concentrating on the science.

If the CEO was vocal like the vast majority of AIM companies, the share price would be much higher.

That route keeps the unpredictable chancers away. At last an AIM company that will react to results rather than spurious nonsense.

Lack of a fitting share price deters investors as they wonder why it languishes.

Couple that with the difficulty in understanding the science.

Lindy will shout at the appropriate time, and if she shouts it means there has been a material event to shout about in the cancer world.

If that point comes (it should) then hang onto your hats.

[octopus100] 12/4/2023 12:02

Though will probably be short term.
Company need to update on their trials - ideally with positive news.
I've lost track of where the 138 patients are at in their recruitment and who and when has been vaccinated.
Also what confuses me is the ongoing melonoma trials think they date back to around 2012/13 and no idea on where they are at or when will expect an update.